Rheumatology - Medtelligence

1-6 of 6

MinuteCE®
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
0.75 credits 6 episodes
- Bernhard Hellmich, MD
- Andreas Kronbichler, MD
- Silke R. Brix, MD, MRCP, SCPR
0.75 credits 6 episodes
Exploring Developments in IgAN and FSGS
Exploring Developments in IgAN and FSGS
CME/CE
Exploring Developments in IgAN and FSGS
0.25 credits
- Howard Trachtman, MD, FASN
- Richard Lafayette, MD, FACP
0.25 credits
Can We Do Better in IgAN?
Can We Do Better in IgAN?
CME/CE
Can We Do Better in IgAN?
- Jonathan Barratt, PhD
- Annette Bruchfeld, MD, PhD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
CME/CE
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
- Jonathan Barratt, PhD
- Donald E. Kohan, MD, PhD
Case-Based Management of AAV
Case-Based Management of AAV
CME/CE
Case-Based Management of AAV
- David Jayne, MD
- Annette Bruchfeld, MD, PhD
Pinpointing the Top Questions about Biosimilars in Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology
CME/CE
Pinpointing the Top Questions about Biosimilars in Rheumatology
- Leonard H. Calabrese, DO
- John R. Tesser, MD